US-based IMRIS has secured CE Mark approval to integrate the next-generation magnetic resonance imaging (MRI) core technology into the VISIUS surgical theatre, clearing the way for its sales and marketing in the European Union.
Based on the Siemens Aera 1.5T(tesla) and Skyra 3.0T MRI scanners, the new imaging technology helps the company provide better image quality, faster 3D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI).
The company said that the integration was to give neurosurgeons an advanced MR scanners with enhanced intraoperative image quality and workflow in an operating room.
In February, the company received approval for these advancements from the US Food and Drug Administration (FDA).
IMRIS president and CEO Jay Miller said: "These high-field intraoperative scanner options will give a hospital’s clinical team state-of-the-art applications and image quality that increase productivity.
"More and more neurosurgical centers are using image guidance with VISIUS iMRI for an expanding list of conditions and procedures and adjunctive interventions beyond brain tumour resections such as laser ablation for tumours and epilepsy using stereotactic tools, deep brain stimulation and other minimally invasive techniques that are designed to improve patient outcomes."
The VISIUS surgical theatre is equipped with a high-field iMRI, which helps surgeons have on-demand access to real-time data and imaging during the procedure as the scanner moves on ceiling-mounted rails.
IMRIS designs and manufactures proprietary intraoperative CTs, head fixation devices, imaging coils and OR tables for use in the multifunctional intraoperative environment.
Image: The IMRIS VISIUS surgical theatre with iMRI has received CE Mark for European distribution. Photo: courtesy of CNW Group/IMRIS Inc.